Regeneron Pharmaceuticals Ownership
| REGN Stock | USD 634.14 26.86 4.06% |
Shares in Circulation | First Issued 1990-03-31 | Previous Quarter 116.2 M | Current Value 113.8 M | Avarage Shares Outstanding 70 M | Quarterly Volatility 39.3 M |
Regeneron |
Regeneron Stock Ownership Analysis
About 91.0% of the company shares are owned by institutional investors. The book value of Regeneron Pharmaceuticals was at this time reported as 273.57. The company has Price/Earnings To Growth (PEG) ratio of 0.94. Regeneron Pharmaceuticals recorded earning per share (EPS) of 38.37. The entity last dividend was issued on the 20th of February 2025. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10915 people. To find out more about Regeneron Pharmaceuticals contact the company at 914 847 7000 or learn more at https://www.regeneron.com.Besides selling stocks to institutional investors, Regeneron Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Regeneron Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Regeneron Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Regeneron Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Regeneron Pharmaceuticals Insider Trades History
Only 1.58% of Regeneron Pharmaceuticals are currently held by insiders. Unlike Regeneron Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Regeneron Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Regeneron Pharmaceuticals' insider trades
Regeneron Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regeneron Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regeneron Pharmaceuticals backward and forwards among themselves. Regeneron Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Regeneron Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Loomis, Sayles & Company Lp | 2024-12-31 | 1.6 M | Amundi | 2024-12-31 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.4 M | Norges Bank | 2024-12-31 | 1.1 M | Northern Trust Corp | 2024-12-31 | 1.1 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 982.1 K | Bank Of America Corp | 2024-12-31 | 940.2 K | International Assets Investment Management, Llc | 2024-09-30 | 880.9 K | Amvescap Plc. | 2024-12-31 | 864.2 K | Vanguard Group Inc | 2024-12-31 | 9.3 M | Blackrock Inc | 2024-12-31 | 8.7 M |
Regeneron Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regeneron Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regeneron Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regeneron Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Joseph LaRosa over two months ago Acquisition by Joseph LaRosa of 2332 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 | ||
Andrew Murphy over a year ago Disposition of tradable shares by Andrew Murphy of Regeneron Pharmaceuticals at 962.87 subject to Rule 16b-3 | ||
Arthur Ryan over a year ago Disposition of tradable shares by Arthur Ryan of Regeneron Pharmaceuticals at 986.58 subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1706 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1706 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 |
Regeneron Pharmaceuticals' latest congressional trading
Congressional trading in companies like Regeneron Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Regeneron Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
| 2025-03-13 | Representative Julie Johnson | Acquired Under $15K | Verify | ||
| 2025-02-13 | Representative Julie Johnson | Acquired Under $15K | Verify | ||
| 2025-02-11 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2024-12-13 | Representative Jonathan Jackson | Acquired $15K to $50K | Verify | ||
| 2024-12-05 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2024-11-15 | Representative Greg Landsman | Acquired Under $15K | Verify | ||
| 2024-11-07 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2024-10-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2024-08-15 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
| 2024-08-14 | Representative Greg Landsman | Acquired Under $15K | Verify | ||
| 2024-05-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-05-11 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2022-04-08 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2021-08-07 | Representative Donald Sternoff Beyer | Acquired Under $15K | Verify |
Regeneron Pharmaceuticals Outstanding Bonds
Regeneron Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regeneron Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regeneron bonds can be classified according to their maturity, which is the date when Regeneron Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| REGENERON PHARMACEUTICALS INC Corp BondUS75886FAF45 | View | |
| REGENERON PHARMACEUTICALS INC Corp BondUS75886FAE79 | View | |
| US75884RBA05 Corp BondUS75884RBA05 | View | |
| REGENCY CTRS L Corp BondUS75884RAV50 | View | |
| US75884RAW34 Corp BondUS75884RAW34 | View | |
| REGENCY CTRS L Corp BondUS75884RAU77 | View | |
| US75884RAZ64 Corp BondUS75884RAZ64 | View | |
| REGENCY CTRS L Corp BondUS75884RAX17 | View |
Regeneron Pharmaceuticals Corporate Filings
| 12th of February 2025 Other Reports | ViewVerify | |
| 7th of February 2025 Other Reports | ViewVerify | |
10K | 5th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 4th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Pair Trading with Regeneron Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regeneron Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regeneron Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Regeneron Stock
| 0.6 | GE | GE Aerospace | PairCorr |
| 0.46 | PLX | Protalix Biotherapeutics | PairCorr |
| 0.46 | LUCD | Lucid Diagnostics | PairCorr |
| 0.42 | WM | Waste Management | PairCorr |
The ability to find closely correlated positions to Regeneron Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regeneron Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regeneron Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regeneron Pharmaceuticals to buy it.
The correlation of Regeneron Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regeneron Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regeneron Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regeneron Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.21) | Earnings Share 38.37 | Revenue Per Share | Quarterly Revenue Growth 0.103 | Return On Assets |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.